Platelet Rich Plasma for Patients With Recurrent Implantation Failure

Patients considered to have recurrent implantation failure will undergo randomization to
receive intrauterine infusions of platelet rich plasma or a placebo of embryo culture media
prior to their embryo transfer. All patients will undergo a blood draw to obtain 60ml of
blood from which 0.5ml of platelet rich plasma will be obtained. Those randomized to receive
the platelet rich plasma will have platelet rich plasma placed into the uterine cavity at
least 48 hours prior to the embryo transfer, while those randomized to receive placebo will
have embryo culture media placed into the uterine cavity at the same point in time. Transfer
outcomes including implantation rate, pregnancy rate, and live birth rate, will be recorded.

Inclusion Criteria:

- All women who have undergone 3 or more embryo (blastocyst stage) transfers without
establishing a clinical pregnancy or 2 or more euploid embryo transfers without
establishing a clinical pregnancy, aged 18 - 45, with a normal uterine cavity
established within 12 months by hysteroscopy or saline infusion sonogram, planning in
vitro fertilization with an embryo transfer at Stanford Fertility and Reproductive
Health. The planned transfer must consist of any of the following: a PGS proven
euploid embryo, a good quality blastocyst from a patient younger than 37, or a donor
oocyte blastocyst.

Exclusion Criteria:

- Abnormal uterine cavity, planning in vitro fertilization with use of a gestational
carrier. patients enrolled in other experimental interventions for RIF will be
excluded. Patients with only poor quality or cleavage stage embryos.